mardi 6 février 2018

Onco Actu du 6 février 2018

2.11 Etiologie - Alimentation

Very hot tea can raise risk of oesophageal cancer, suggests study [The Guardian]

Hot tea tied to higher cancer risk for smokers and drinkers [Reuters]

3.1.1 Prévention - Tabac - e-cigs

E-cigarettes 'should be on prescription' [BBC News]

UK experts urge smokers to switch to e-cigs for big health gains [Reuters]

E-cigarettes and heated tobacco products: evidence review [Public Health England]

E-cigarettes should be on sale in hospital shops, health body says [The Guardian]

3.3 Prévention - Vaccins

HPV vaccine offered to men who have sex with men in England [BBC News]

3.6 Prévention - Activité physique

Physical Inactivity Linked to Higher Risk of Lung, Head/Neck Cancers [Roswell Park Cancer Center]

4.2 Dép., diag. & prono. - Génome

Nanopore Sequencing: The Future of NGS? [Genohub]

5. Traitements

Progress in the treatment of ALL, NSCLC, urothelial cancer, melanoma, colorectal and breast cancers according to year in review articles published in the Nature Reviews Clinical Oncology [ESMO]

Opinion: Do Not Believe the Hype [The Scientist]

5.10 Traitements - Essais

Publication Highlights Key Questions as Basket Studies Proliferate [Genome Web]

5.12 Immunothérapies

Gut Bacteria Influence Effectiveness of a Type of Immunotherapy [NCI]

5.12.10 Immunothérapies - Fusions et acquisitions

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch [EndPoints]

5.12.3 Immunothérapies-combinaisons

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they’re not changing medical practice — yet [EndPoints]

More Questions Than Answers For Bristol-Myers [Forbes]

Bristol claims victory in crucial immunotherapy trial, but results raise some questions [STAT]

Bristol-Myers scores big, wows checkpoint field with an early hit on Opdivo-Yervoy combo for lung cancer [EndPoints]

Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB) [BMS]

5.4 Traitements - Economie

NICE, the NHS, and Cancer Drugs [JAMA]

5.5.14 ASCO (vessie)

New Model Predicts Survival for People With Bladder Cancer Receiving Immunotherapy [ASCO]

5.5.3 ASCO (prostate)

Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer [Astellas]

Apalutamide Delays Prostate Cancer Metastases by More Than Two Years [ASCO]

Chemotherapy Added to Hormone Therapy for Prostate Cancer Improves Quality of Life [ASCO]

Pfizer's Xtandi delays prostate cancer spread in early stage disease [Reuters]

Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer [EndPoints]

5.5.4 ASCO (immunothérapies)

Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer, With Fewer Side Effects [ASCO]

Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People with Advanced Kidney Cancer [Genentech]

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data [EndPoints]

6.6 Publications

Meet the New Editor-in-Chief of Cancer Research, Chi Van Dang, MD, PhD [Cancer Research Catalyst]

6.8 Communication

Where Does the News Hype Come From? [In the Pipeline]